Toripalimab in combination with chemotherapy effectively suppresses local recurrence and metastatic sarcomatoid renal cell carcinoma:A case report  

作　　者：Ming-Zhu Gao Nian-Fei Wang Jin-You Wang Li Ma Yu-Cai Yang 

机构地区：[1]Department of Oncology,the Second Affiliated Hospital of Anhui Medical University,Hefei 230601,China [2]Department of Urology,the Second Affiliated Hospital of Anhui Medical University,Hefei 230601,China [3]Department of Pathology,the Second Affiliated Hospital of Anhui Medical University,Hefei 230601,China

出　　处：《World Journal of Clinical Cases》2024年第28期6230-6236,共7页世界临床病例杂志

基　　金：The Health Research Program of Anhui Province,China,No.AHWJ2022b048;The Research Foundation of Anhui Medical University,China,No.2021xkj164;The Clinical Scientific Research Cultivation Project of the Second Affiliated Hospital of Anhui Medical University,China,No.2021LCZD04.

摘　　要：BACKGROUND Sarcomatoid renal cell carcinoma(SRCC)is a rare variant of renal cell carcinoma associated with an unfavorable prognosis.The efficacy of conventional chemo-therapy and targeted therapies are limited,whereas the emergence of immune checkpoint inhibitor has introduced new avenues for managing advanced SRCC.CASE SUMMARY A 77-year-old female patient was referred to our hospital following the incidental detection of a right kidney tumor without specific symptoms.The tumor was successfully resected,and subsequent pathological examination confirmed SRCC.She experienced both local recurrence and distant metastasis eight months after the initial laparoscopic resection.Following six cycles of toripalimab combined with pirarubicin chemotherapy,the patient achieved a partial response.Subse-quently,the patient attained an almost-complete continuous response to toripa-limab monotherapy maintenance for an additional six cycles.She has not experienced disease progression for 15 months,and her overall survival has reached 24 months thus far.CONCLUSION Combination therapy with programmed death 1 antibodies and cytotoxic agents may be a recommended first-line treatment approach for SRCC.

关 键 词：Renal cell carcinoma Sarcomatoid dedifferentiation Immune checkpoint inhibitor CHEMOTHERAPY Case report 

分 类 号：R737.11[医药卫生—肿瘤]